Insparin Therapeutics Appoints Dr. Alex Gaidamaka as Chief Technology Officer
FOR IMMEDIATE RELEASE:
Houston, TX — Sept-23-2025 — Insparin Therapeutics, a biotechnology company developing insulin-independent therapies for severe insulin resistance syndromes, announced today the appointment of Dr. Alex Gaidamaka, Ph.D., D.V.M., as its new Chief Technology Officer, effective immediately.
Dr. Gaidamaka brings more than 30 years of biopharmaceutical industry experience, with deep expertise across all aspects of biologics CMC development, including production process and analytical development, validations, technology transfer, and GMP manufacturing across multiple technology platforms. He also has substantial regulatory experience from senior roles at Sanofi Group, AmpliPhi Biosciences, Personalized OncoTherapeutics, XyloCor Therapeutics, and other companies.
“Alex’s unparalleled experience in biologics development and manufacturing makes him an invaluable addition to Insparin’s leadership team,” said Rohan Dhurandhar, Chief Executive Officer of Insparin Therapeutics. “His expertise in CMC and regulatory strategy will be critical as we scale our operations and move our lead programs closer to the clinic.”
Insparin Therapeutics is currently advancing a pipeline of first-in-class therapeutics for severe insulin resistance and severe insulin resistance syndromes—devastating, often pediatric-onset conditions for which there are currently no approved insulin-independent treatments.
Dr. Gaidamaka holds a Ph.D. in microbiology and immunology and is also a Doctor of Veterinary Medicine. His appointment comes at a pivotal moment for Insparin, as the company prepares to expand its R&D capabilities, engage with regulators, and establish a robust manufacturing foundation to support clinical development.
“I am excited to join Insparin at such an important stage,” said Dr. Gaidamaka. “The company’s mission to bring new therapies to patients facing severe metabolic challenges resonates deeply with me, and I look forward to contributing my expertise to accelerate the path from lab to clinic.”